Astria Therapeutics, Inc.

    Jurisdiction
    United States
    ISIN
    US04635X1028 (ATXS)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    2 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    4 / 7

    Profile

    Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €0.00
    Gross margin
    0.0%
    EBIT
    -€112.09M
    EBIT margin
    0.0%
    Net income
    -€99.73M
    Net margin
    0.0%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €3.58M +∞% -€127.41M +27.8%
    €4.46M +24.5% -€132.62M +4.1%
    €50.89M +1,040.7% -€119.44M -9.9%

    Dividends

    No dividend payouts

    Earnings Calls

    Latest earnings call: November 13, 2023

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 179K $956.72K +141K Buy

    Add to watchlist

    Notifications